Facebook
Twitter
LinkedIn
Forward
Sarcopenic obesity presents numerous risks to health and quality of life.
|
This webinar re-playing the popular session from the Obesity Medicine Conference 2021 provides a brief overview of FDA-approved anti-obesity medications (AOM’s).
|
The global COVID-19 pandemic has turned our patient’s lives and routines upside down.
|
Patients and Primary Care Clinicians face numerous difficulties in providing effective, affordable weight loss and maintenance programs.
|
During this webinar, Dr.
|
As the choices available for anti-obesity pharmacotherapy increase, clinicians are faced with options for addressing key clinical scenarios.
|
Obesity is one of the leading causes of preventable death. Obesity-related increases metabolic and cardiovascular risk occur at a lower body mass index in Asian adults.
|
The OMA Obesity Algorithm has finished being revised for 2023 and is now available. In this webinar, Dr. Justin Tondt will highlight the changes from the previous edition.
|
CME/CE Expiration Date: 6/29/2026* *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
|
Dr. Weber will present and discuss case examples that will increase familiarity with antiobesity medication indications, contraindications, side effect profiles, and medication interactions.
|